Skip to main content
NCBI home page
Gut logoLink to Gut
. 1996;38(Suppl 2):S24–S30. doi: 10.1136/gut.38.suppl_2.s24

Comprehensive control (or elimination) of hepatitis B virus transmission in the United States.

F B Hollinger 1
PMCID: PMC1398039  PMID: 8786049

Abstract

In the United States, the reported rate of hepatitis B has declined by over 50% since 1987, probably as a result of vaccination programmes, behavioural changes, refinements in blood screening procedures, and the availability of virus inactivated blood components. The majority of new hepatitis B infections occur in 20-39 year olds, and perinatal transmission is uncommon except in certain at risk groups. Initial efforts to control hepatitis B in the US were targeted at high risk groups, including health care personnel. Then, in 1988, the Centers for Disease Control and Prevention (CDC) recommended screening of all pregnant females for hepatitis B surface antigen and full immunisation of infants born to those testing positive. A recommendation for universal immunisation of infants was endorsed in 1991. Compliance has been slow but progressive. The CDC also has recommended 'catch up' immunisation of adolescents and high risk children and adults. Demonstration projects suggest that these can be successful, given the provision of free or low cost vaccine and appropriate support. Hepatitis B vaccination has been shown to be cost effective and should be integrated into the routine childhood immunisation schedule. Responses to hepatitis B vaccine have largely been shown to be durable, although at least one booster dose after five to 10 years seems prudent, especially if a low dose, yeast derived vaccine has been used.

Full text

PDF
S24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter M. J., Hadler S. C., Margolis H. S., Alexander W. J., Hu P. Y., Judson F. N., Mares A., Miller J. K., Moyer L. A. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 1990 Mar 2;263(9):1218–1222. [PubMed] [Google Scholar]
  2. Ayus J. C., Krothapalli R. K. Effect of bicarbonate administration on cardiac function. Am J Med. 1989 Jul;87(1):5–6. doi: 10.1016/s0002-9343(89)80475-9. [DOI] [PubMed] [Google Scholar]
  3. Bloom B. S., Hillman A. L., Fendrick A. M., Schwartz J. S. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 1993 Feb 15;118(4):298–306. doi: 10.7326/0003-4819-118-4-199302150-00009. [DOI] [PubMed] [Google Scholar]
  4. Freed G. L., Bordley W. C., Clark S. J., Konrad T. R. Universal hepatitis B immunization of infants: reactions of pediatricians and family physicians over time. Pediatrics. 1994 May;93(5):747–751. [PubMed] [Google Scholar]
  5. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  6. Hollinger F. B. Controlling hepatitis B virus transmission in North America. The North American Regional Study Group. Vaccine. 1990 Mar;8 (Suppl):S122–S138. doi: 10.1016/0264-410x(90)90232-b. [DOI] [PubMed] [Google Scholar]
  7. Kim S. C., Sinai L. N., Casey R., Pinto-Martin J. A. Universal hepatitis B immunization. Pediatrics. 1995 May;95(5):764–766. [PubMed] [Google Scholar]
  8. Krahn M., Detsky A. S. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making. 1993 Jan-Mar;13(1):4–20. doi: 10.1177/0272989X9301300103. [DOI] [PubMed] [Google Scholar]
  9. Lau Y. L., Tam A. Y., Ng K. W., Tsoi N. S., Lam B., Lam P., Yeung C. Y. Response of preterm infants to hepatitis B vaccine. J Pediatr. 1992 Dec;121(6):962–965. doi: 10.1016/s0022-3476(05)80352-x. [DOI] [PubMed] [Google Scholar]
  10. Margolis H. S., Coleman P. J., Brown R. E., Mast E. E., Sheingold S. H., Arevalo J. A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA. 1995 Oct 18;274(15):1201–1208. [PubMed] [Google Scholar]
  11. Margolis H. S. Prevention of acute and chronic liver disease through immunization: hepatitis B and beyond. J Infect Dis. 1993 Jul;168(1):9–14. doi: 10.1093/infdis/168.1.9. [DOI] [PubMed] [Google Scholar]
  12. Stevens C. E., Toy P. T., Tong M. J., Taylor P. E., Vyas G. N., Nair P. V., Gudavalli M., Krugman S. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA. 1985 Mar 22;253(12):1740–1745. [PubMed] [Google Scholar]
  13. Wainwright R. B., McMahon B. J., Bulkow L. R., Hall D. B., Fitzgerald M. A., Harpster A. P., Hadler S. C., Lanier A. P., Heyward W. L. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989 Apr 28;261(16):2362–2366. [PubMed] [Google Scholar]
  14. West D. J., Margolis H. S. Prevention of hepatitis B virus infection in the United States: a pediatric perspective. Pediatr Infect Dis J. 1992 Oct;11(10):866–874. doi: 10.1097/00006454-199210000-00012. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES